CA2051439A1 - Liposomal targeting of ischemic tissue - Google Patents

Liposomal targeting of ischemic tissue

Info

Publication number
CA2051439A1
CA2051439A1 CA 2051439 CA2051439A CA2051439A1 CA 2051439 A1 CA2051439 A1 CA 2051439A1 CA 2051439 CA2051439 CA 2051439 CA 2051439 A CA2051439 A CA 2051439A CA 2051439 A1 CA2051439 A1 CA 2051439A1
Authority
CA
Canada
Prior art keywords
ischemic tissue
liposomes
liposomal targeting
liposomal
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2051439
Other languages
French (fr)
Other versions
CA2051439C (en
Inventor
John D. Baldeschwieler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexstar Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2051439A1 publication Critical patent/CA2051439A1/en
Application granted granted Critical
Publication of CA2051439C publication Critical patent/CA2051439C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates in general to the field of biochemistry and medicine, and more particularly to the use of liposomes in the diagnosis and treatment of ischemic tissue. Liposomes of a size of less than 200 nanometers target ischemic tissue and preferentially deliver active agents to infarcted areas in the absence of antibodies bound to the liposomes to effect the delivery.
CA 2051439 1989-04-18 1990-04-13 Liposomal targeting of ischemic tissue Expired - Lifetime CA2051439C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33968289A 1989-04-18 1989-04-18
US07/339,682 1989-04-18

Publications (2)

Publication Number Publication Date
CA2051439A1 true CA2051439A1 (en) 1990-10-19
CA2051439C CA2051439C (en) 1999-03-23

Family

ID=23330138

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2051439 Expired - Lifetime CA2051439C (en) 1989-04-18 1990-04-13 Liposomal targeting of ischemic tissue

Country Status (1)

Country Link
CA (1) CA2051439C (en)

Also Published As

Publication number Publication date
CA2051439C (en) 1999-03-23

Similar Documents

Publication Publication Date Title
DK0469082T3 (en) Liposomal targeting of ischemic tissues
CA2196780A1 (en) A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2253837A1 (en) Therapeutic uses of bpi protein products for human meningococcemia
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
CA2169087A1 (en) Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same
BG103552A (en) Therapeutical forms
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
CA2203033A1 (en) Compounds and compositions for delivering active agents
ATE238038T1 (en) LIPOSOMAL FORMULATIONS OF MITOXANTRONE
CA2403345A1 (en) System for the controlled delivery of an active material to a dental site
HUT55220A (en) Process for producing pharmaceutical composition suitable for systemic administration through the skin and comprising deprenyl as active ingredient
CA2032059A1 (en) Wound treatment employing biologically active peptides
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
AU6553790A (en) Pharmazeutische praparate
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
EP0744176A3 (en) Methods for inhibiting bone loss
RU94036668A (en) Agent for treatment of oral cavity disease
CA2091134A1 (en) Therapeutic agent for threatened abortion
CA2051439A1 (en) Liposomal targeting of ischemic tissue
WO1996040627A3 (en) Thiocationic lipids, pharmaceutical compositions and methods of use thereof
NZ335401A (en) Therapeutic uses of BPI protein products in cystic fibrosis patients
CA2134783A1 (en) Use of remacemide for the treatment of parkinson's disease

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry